Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127718861 | 12771886 | 1 | I | 201604 | 20160912 | 20160922 | 20160922 | EXP | GB-MHRA-EYC 00144852 | GB-TEVA-693316ACC | TEVA | 85.00 | YR | M | Y | 0.00000 | 20160922 | PH | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127718861 | 12771886 | 1 | PS | BISOPROLOL | BISOPROLOL | 1 | Oral | 10 MILLIGRAM DAILY; EVERY MORNING | Y | U | 19982 | 10 | MG | QD | |||||
127718861 | 12771886 | 2 | SS | RAMIPRIL. | RAMIPRIL | 1 | Oral | 5MG EVERY MORNING AND 2.5MG EVERY NIGHT | Y | U | 77470 | 7.5 | MG | ||||||
127718861 | 12771886 | 3 | SS | DIGOXIN. | DIGOXIN | 1 | Oral | 125 MICROGRAM DAILY; | Y | U | 0 | 125 | UG | QD | |||||
127718861 | 12771886 | 4 | C | ATORVASTATIN | ATORVASTATIN | 1 | 0 | ||||||||||||
127718861 | 12771886 | 5 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | 0 | ||||||||||||
127718861 | 12771886 | 6 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | 0 | ||||||||||||
127718861 | 12771886 | 7 | C | FINASTERIDE. | FINASTERIDE | 1 | 0 | ||||||||||||
127718861 | 12771886 | 8 | C | FOLIC ACID. | FOLIC ACID | 1 | 0 | ||||||||||||
127718861 | 12771886 | 9 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | ||||||||||||
127718861 | 12771886 | 10 | C | HUMALOG MIX75/25 | INSULIN LISPRO | 1 | 0 | ||||||||||||
127718861 | 12771886 | 11 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | 0 | ||||||||||||
127718861 | 12771886 | 12 | C | LINAGLIPTIN | LINAGLIPTIN | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127718861 | 12771886 | 1 | Left ventricular dysfunction |
127718861 | 12771886 | 2 | Hypertension |
127718861 | 12771886 | 3 | Left ventricular dysfunction |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127718861 | 12771886 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127718861 | 12771886 | Acute kidney injury | |
127718861 | 12771886 | Atrial fibrillation | |
127718861 | 12771886 | Atrioventricular block | |
127718861 | 12771886 | Bradycardia | |
127718861 | 12771886 | Hyperkalaemia | |
127718861 | 12771886 | Lethargy | |
127718861 | 12771886 | Malaise | |
127718861 | 12771886 | Thirst | |
127718861 | 12771886 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127718861 | 12771886 | 1 | 20160419 | 0 | ||
127718861 | 12771886 | 2 | 20160419 | 0 | ||
127718861 | 12771886 | 3 | 20160419 | 0 |